Interferon alpha-2b therapy in chronic hepatitis delta

Hepatitis Monthly

Volumn 14, Issue 3, 2014, Pages

  Keshvari, Maryam ^a,b   Alavian, Seyed Moayed ^b   Sharaf, Heidar ^b   Karimi, Gharib ^a   Gholami Fesharaki, Mohammad ^c  

^a HIGH INSTITUTE FOR RESEARCH AND EDUCATION IN TRANSFUSION MEDICINE   (Iran)

^b Middle East Liver Diseases Center (MELD Centers)   (Iran)

^c TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Hepatitis D; Interferon alpha; Iran

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; PDFERON B; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DELTA AGENT HEPATITIS; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HISTOLOGY; HUMAN; IRAN; LIVER FIBROSIS; MALE; MIXED INFECTION; PATIENT COMPLIANCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84898461082     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.15729     Document Type: Article

References (34)

1. Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F, et al. Immunofuorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18(12):997-1003.
2. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364(4):322-331.
3. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378(9785):73-85.
4. Husa P, Linhartova A, Nemecek V, Husova L. Hepatitis D. Acta Virol. 2005;49(4):219-225.
5. Alavian S. Hepatitis D Virus Infection; Iran, Middle East and Central Asia. Hepat Mon. 2005:137-143.
6. Yurdaydin C, Bozkaya H, Karaaslan H, Onder FO, Erkan OE, Yalcin K, et al. A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis. J Viral Hepat. 2007;14(11):812-816.
7. Farci P, Chessa L, Balestrieri C, Serra G, Lai ME. Treatment of chronic hepatitis D. J Viral Hepat. 2007;14 Suppl 1:58-63.
8. Madejon A, Cotonat T, Bartolome J, Castillo I, Carreno V. Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response. Hepatology. 1994;19(6):1331-1336.
9. Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat. 2010;17(11):749-756.
10. Smedile A, Niro MG, Rizzetto M. Detection of serum HDV RNA by RT-PCR. Methods Mol Med. 2004;95:85-93.
11. Gheorghe L, Iacob S, Simionov I, Vadan R, Constantinescu I, Ca-runtu F, et al. Weight-based dosing regimen of peg-interferon alpha-2b for chronic hepatitis delta: a multicenter Romanian trial. J Gastrointestin Liver Dis. 2011;20(4):377-382.
12. Ho E, Deltenre P, Nkuize M, Delwaide J, Colle I, Michielsen P, et al. Coinfection of hepatitis B and hepatitis delta virus in Belgium: a multicenter BASL study. Prospective epidemiology and comparison with HBV mono-infection. J Med Virol. 2013;85(9):1513-1517.
13. Kaymakoglu S, Karaca C, Demir K, Poturoglu S, Danalioglu A, Badur S, et al. Alpha interferon and ribavirin combination therapy of chronic hepatitis D. Antimicrob Agents Chemother. 2005;49(3):1135-1138.
14. Niro GA, Smedile A, Ippolito AM, Ciancio A, Fontana R, Olivero A, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol. 2010;53(5):834-840.
15. Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med. 1994;330(2):88-94.
16. Gaudin JL, Faure P, Godinot H, Gerard F, Trepo C. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver. 1995;15(1):45-52.
17. Lau JY, King R, Tibbs CJ, Catterall AP, Smith HM, Portmann BC, et al. Loss of HBsAg with interferon-alpha therapy in chronic hepatitis D virus infection. J Med Virol. 1993;39(4):292-296.
18. Battegay M, Simpson LH, Hoofnagle JH, Sallie R, Di Bisceglie AM. Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis. J Med Virol. 1994;44(4):389-392.
19. Rosina F, Pintus C, Meschievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human inter-feron-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology. 1991;13(6):1052-1056.
20. Gunsar F, Akarca US, Ersoz G, Kobak AC, Karasu Z, Yuce G, et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther. 2005;10(6):721-726.
21. Yurdaydin C, Bozkaya H, Onder FO, Senturk H, Karaaslan H, Ak-dogan M, et al. Treatment of chronic delta hepatitis with lami-vudine vs lamivudine + interferon vs interferon. J Viral Hepat. 2008;15(4):314-321.
22. Gulsun S, Tekin R, Bozkurt F. Treatment of chronic delta hepatitis: a nine-year retrospective analysis. Hepat Mon. 2011;11(9):731-735.
23. Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, et al. Long-term beneft of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fbrosis. Gastroenter-ology. 2004;126(7):1740-179.
24. Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, et al. Pe-gylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006;44(3):713-720.
25. Abbas Z, Khan MA, Salih M, Jafri W. Interferon alpha for chronic hepatitis D. Cochrane Database Syst Rev. 2011(12):CD006002.
26. Brichler S, Setshedi M, Renou C. Resolution of chronic hepatitis delta infection after fve years of peginterferon-adefovir: lessons from a case report. Clin Res Hepatol Gastroenterol. 2013;37(3):e81-e84.
27. Lau DT, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology. 1999;117(5):1229-1233.
28. Alavian SM, Tabatabaei SV, Behnava B, Rizzetto M. Standard and pegylated interferon therapy of HDV infection: A systematic review and meta- analysis. J Res Med Sci. 2012;17(10):967-974.
29. Karaca C, Soyer OM, Baran B, Ormeci AC, Gokturk S, Aydin E, et al. Efficacy of pegylated interferon-alpha treatment for 24 months in chronic delta hepatitis and predictors of response. Antivir Ther. 2013;18(4):561-566.
30. Lamers MH, Kirgiz OO, Heidrich B, Wedemeyer H, Drenth JP. Interferon-alpha for patients with chronic hepatitis delta: a systematic review of randomized clinical trials. Antivir Ther. 2012;17(6):1029-1037.
31. Mansour W, Ducancelle A, Le Gal F, Le Guillou-Guillemette H, Ab-gueguen P, Pivert A, et al. Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, teno-fovir and emtricitabine. J Clin Virol. 2010;47(1):97-99.
32. Dastgerdi ES, Herbers U, Tacke F. Molecular and clinical aspects of hepatitis D virus infections. World J Virol. 2012;1(3):71-78.
33. Hadziyannis SJ. Use of alpha-interferon in the treatment of chronic delta hepatitis. J Hepatol. 1991;13 Suppl 1:S21-S26.
34. Gish RG, Yi DH, Kane S, Clark M, Mangahas M, Baqai S, et al. Coin-fection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. J Gastroenterol Hepatol. 2013;28(9):1521-1525.